Evidence of clinically significant extravascular stores of factor IX

Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide

(2011) H. Ostergaard et al.   BLOOD

Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients

(2011) A. D. Shapiro et al.   BLOOD

Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B

(2011) C. Negrier et al.   BLOOD

A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing

(2011) S. BJÖRKMAN   HAEMOPHILIA

Factor IX replacement to cover total knee replacement surgery in haemophilia B: a single-centre experience, 2000-2010

(2011) J. UPRICHARD et al.   HAEMOPHILIA

Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia

(2010) P. W. COLLINS et al.   HAEMOPHILIA

The heparin-binding exosite of factor IXa is a critical regulator of plasma thrombin generation and venous thrombosis

(2008) Y. Buyue et al.   BLOOD